

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	ı	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/883,572 06/13		06/18/2001	Reto Naef	4-30754A	2901
1095	7590 11/04/2004			EXAMINER	
NOVARTIS CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 430/2				HAGHIGHATIAN, MINA	
				ART UNIT	PAPER NUMBER
EAST HAN	OVER, N	NJ 07936-1080	1616	-	
				DATE MAILED: 11/04/200	\$

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. Applicant(s) NAEF, RETO 09/883,572 Notice of Abandonment Examiner Art Unit 1616 Mina Haghighatian -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--This application is abandoned in view of: 1. Applicant's failure to timely file a proper reply to the Office letter mailed on <u>07 April 2004</u>. (a) A reply was received on _____ (with a Certificate of Mailing or Transmission dated _____), which is after the expiration of the period for reply (including a total extension of time of _____ month(s)) which expired on _____. (b) A proposed reply was received on _____, but it does not constitute a proper reply under 37 CFR 1.113 (a) to the final rejection. (A proper reply under 37 CFR 1.113 to a final rejection consists only of: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114). (c) A reply was received on _____ but it does not constitute a proper reply, or a bona fide attempt at a proper reply, to the nonfinal rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below). (d) No reply has been received. 2. Applicant's failure to timely pay the required issue fee and publication fee, if applicable, within the statutory period of three months from the mailing date of the Notice of Allowance (PTOL-85). (a) The issue fee and publication fee, if applicable, was received on _____ (with a Certificate of Mailing or Transmission dated), which is after the expiration of the statutory period for payment of the issue fee (and publication fee) set in the Notice of Allowance (PTOL-85). (b) The submitted fee of \$____ is insufficient. A balance of \$____ is due. The issue fee required by 37 CFR 1.18 is \$_____. The publication fee, if required by 37 CFR 1.18(d), is \$____. (c) The issue fee and publication fee, if applicable, has not been received. 3. Applicant's failure to timely file corrected drawings as required by, and within the three-month period set in, the Notice of Allowability (PTO-37). (a) Proposed corrected drawings were received on _____ (with a Certificate of Mailing or Transmission dated _____), which is after the expiration of the period for reply. (b) No corrected drawings have been received. 4. The letter of express abandonment which is signed by the attorney or agent of record, the assignee of the entire interest, or all of the applicants. 5. The letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFR 1.34(a)) upon the filing of a continuing application. 6. The decision by the Board of Patent Appeals and Interference rendered on _____ and because the period for seeking court review of the decision has expired and there are no allowed claims. 7. The reason(s) below: Multiple calles made to Novartis to confirm the abandonment from 10/26/04 to 10/28/04, with no success. The telephone number provided to the PTO by Ms. Brouillette was no longer in service. Petitions to revive under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(b) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(b) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(b) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(b) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(b) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(b) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(b) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(b) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(b) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(b) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(b) or (b), or requests to withdraw the holding of abandonmerit under 37 CFR 1.137(b) or (b) minimize any negative effects on patent term.